Please assess the completion status of the following clinical trial:

Trial Title: TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 45 to 80 years~* Persistent urinary albumin:creatinine ratio (UACR) ≥ 2.5 mg/mmol (\~25 mg/g)~* Willing to sign informed consent~Exclusion Criteria:~Diagnosis of type 1 diabetes mellitus~* eGFR \< 25 ml/min/1.73m2~* UACR \> 3500 mg/g~* Concurrent treatment with SGLT2 inhibitor~* Receiving immunosuppressive therapy within 6 months prior to enrolment~* History of diabetic ketoacidosis~* Active malignancy aside from treated squamous cell or basal cell carcinoma of the skin.~* Initiation or changes in the dose of interventions in the renin-angiotensinaldosterone- system, diuretics, GLP-1 receptor agonists within 6 weeks of screening will not be allowed.~* Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following:~  * History of active inflammatory bowel disease within the last six months;~ * Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;~ * Gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within last six months;~ * Pancreatic injury or pancreatitis within the last six months;~ * Evidence of hepatic disease as determined by any one of the following: ALT or AST values exceeding 3x ULN at the screening visit, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt;~ * Evidence of urinary obstruction or difficulty in voiding at screening~* History of severe hypersensitivity or contraindications to dapagliflozin~* Subjects who, in the assessment of the investigator, may be at risk for dehydration or volume depletion that may affect the interpretation of efficacy or safety data~* Participation in any clinical intervention study within 3 months prior to initial dosing.~* History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during the screening.~* History of noncompliance to medical regimens or unwillingness to comply with the study protocol.~* Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Dapagliflozin 10mg/day (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).